Refine
Has Fulltext
- no (44)
Year of publication
Document Type
- Other (44) (remove)
Is part of the Bibliography
- yes (44) (remove)
Keywords
- Dialysis patients (1)
- Dopamine (1)
- Epigenetic Biomarkers (1)
- Inertial measurement units (1)
- Intelligence (1)
- Mortality (1)
- Polygenic Risk Score (1)
- Reward Anticipation (1)
- Serum intact-parathyroid hormone level (1)
- affect (1)
Institute
- Department Sport- und Gesundheitswissenschaften (44) (remove)
When local poverty is more important than your income: Mental health in minorities in inner cities
(2015)
We investigated the possibility to identify motor units (MUs) with high-density surface electromyography (HDEMG) over experimental sessions in different days. 10 subjects performed submaximal knee extensions across three sessions in three days separated by one week, while EMG was recorded from the vastus medialis muscle with high-density electrode grids. The shapes of the MU action potentials (MUAPs) over multiple channels extracted from HDEMG decomposition were matched across sessions by cross-correlation. Forty and twenty percent of the MUs decomposed could be tracked across two and three sessions, respectively (average cross correlation 0.85 +/- 0.04). The estimated properties of the matched motor units were similar across the sessions. For example, mean discharge rate and recruitment thresholds were measured with an intra-class correlation coefficient (ICCs) > 0.80. These results strongly suggest that the same MUs were indeed identified across sessions. This possibility will allow monitoring changes in MU properties following interventions or during the progression of neuromuscular disorders.
Background: Evidence that home telemonitoring (HTM) for patients with chronic heart failure (CHF) offers clinical benefit over usual care is controversial as is evidence of a health economic advantage. Therefore the CardioBBEAT trial was designed to prospectively assess the health economic impact of a dedicated home monitoring system for patients with CHF based on actual costs directly obtained from patients’ health care providers.
Methods: Between January 2010 and June 2013, 621 patients (mean age 63,0 ± 11,5 years, 88 % male) with a confirmed diagnosis of CHF (LVEF ≤ 40 %) were enrolled and randomly assigned to two study groups comprising usual care with and without an interactive bi-directional HTM (Motiva®). The primary endpoint was the Incremental Cost-Effectiveness Ratio (ICER) established by the groups’ difference in total cost and in the combined clinical endpoint “days alive and not in hospital nor inpatient care per potential days in study” within the follow up of 12 months. Secondary outcome measures were total mortality and health related quality of life (SF-36, WHO-5 and KCCQ).
Results: In the intention-to-treat analysis, total mortality (HR 0.81; 95% CI 0.45 – 1.45) and days alive and not in hospital (343.3 ± 55.4 vs. 347.2 ± 43.9; p = 0.909) were not significantly different between HTM and usual care. While the resulting primary endpoint ICER was not positive (-181.9; 95% CI −1626.2 ± 1628.9), quality of life assessed by SF-36, WHO-5 and KCCQ as a secondary endpoint was significantly higher in the HTW group at 6 and 12 months of follow-up.
Conclusions: The first simultaneous assessment of clinical and economic outcome of HTM in patients with CHF did not demonstrate superior incremental cost effectiveness compared to usual care. On the other hand, quality of life was improved. It remains open whether the tested HTM solution represents a useful innovative approach in the recent health care setting.
Preclinical studies in cell culture systems as well as in whole animal chronic kidney disease (CKD) models showed that parathyroid hormone (PTH), oxidized at the 2 methionine residues (positions 8 and 18), caused a loss of function. This was so far not considered in the development of PTH assays used in current clinical practice. Patients with advanced CKD are subject to oxidative stress, and plasma proteins (including PTH) are targets for oxidants. In patients with CKD, a considerable but variable fraction (about 70 to 90%) of measured PTH appears to be oxidized. Oxidized PTH (oxPTH) does not interact with the PTH receptor resulting in loss of biological activity. Currently used intact PTH (iPTH) assays detect both oxidized and non-oxPTH (n-oxPTH). Clinical studies demonstrated that bioactive, n-oxPTH, but not iPTH nor oxPTH, is associated with mortality in CKD patients.